Urogen Pharma (NASDAQ:URGN) Insider Mark Schoenberg Sells 10,000 Shares of Stock

Urogen Pharma (NASDAQ:URGN) insider Mark Schoenberg sold 10,000 shares of the company’s stock in a transaction that occurred on Thursday, July 9th. The shares were sold at an average price of $40.00, for a total value of $400,000.00. Following the sale, the insider directly owned 119,763 shares in the company, valued at approximately $4,790,520. This represents a 7.71% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Mark Schoenberg also recently made the following trade(s):

• On Monday, June 22nd, Mark Schoenberg sold 10,000 shares of Urogen Pharma stock. The stock was sold at an average price of $35.01, for a total transaction of $350,100.00.
• On Monday, June 8th, Mark Schoenberg sold 5,222 shares of Urogen Pharma stock. The shares were sold at an average price of $27.30, for a total transaction of $142,560.60.

Urogen Pharma Stock Down 4.2%

URGN stock traded down $1.67 during trading on Friday, hitting $38.56. 1,281,162 shares of the company’s stock traded hands, compared to its average volume of 656,502. The stock has a market capitalization of $1.88 billion, a price-to-earnings ratio of -14.02 and a beta of 1.56. Urogen Pharma has a 52 week low of $13.79 and a 52 week high of $40.35. The stock has a fifty day moving average price of $31.28 and a two-hundred day moving average price of $24.43.

Urogen Pharma (NASDAQ:URGN) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.01. The business had revenue of $50.96 million during the quarter, compared to the consensus estimate of $44.83 million. As a group, equities research analysts expect that Urogen Pharma will post -0.88 EPS for the current fiscal year.

Hedge Funds Weigh In On Urogen Pharma

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. AQR Capital Management LLC increased its position in Urogen Pharma by 347.5% in the 1st quarter. AQR Capital Management LLC now owns 114,066 shares of the company’s stock valued at $1,262,000 after acquiring an additional 88,577 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Urogen Pharma by 7.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,320 shares of the company’s stock worth $258,000 after acquiring an additional 1,653 shares during the period. Jane Street Group LLC grew its stake in shares of Urogen Pharma by 94.3% in the first quarter. Jane Street Group LLC now owns 51,177 shares of the company’s stock worth $566,000 after purchasing an additional 24,839 shares in the last quarter. Cetera Investment Advisers bought a new position in shares of Urogen Pharma in the second quarter worth $361,000. Finally, JPMorgan Chase & Co. increased its holdings in shares of Urogen Pharma by 5.2% during the second quarter. JPMorgan Chase & Co. now owns 390,364 shares of the company’s stock valued at $5,348,000 after purchasing an additional 19,405 shares during the period. 91.29% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have commented on URGN. Oppenheimer restated an “outperform” rating on shares of Urogen Pharma in a research note on Tuesday, June 2nd. UBS Group reissued a “buy” rating on shares of Urogen Pharma in a report on Thursday. LADENBURG THALM/SH SH assumed coverage on Urogen Pharma in a research report on Monday, May 11th. They set a “buy” rating and a $43.00 price objective for the company. D. Boral Capital restated a “buy” rating and set a $33.00 price objective on shares of Urogen Pharma in a research note on Tuesday, March 31st. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Urogen Pharma in a research report on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Urogen Pharma currently has an average rating of “Moderate Buy” and an average target price of $39.50.

Urogen Pharma Company Profile

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.